The Effects of External Counter Pulsation Therapy on Circulating Endothelial Progenitor Cells
The objectives of the study are to test the hypothesis that external counter pulsation therapy (ECPT) provides clinical benefit by improving the number and function of endothelial progenitor cells (EPCs) in peripheral blood of patients with angina pectoris.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effects of External Counter Pulsation Therapy (ECPT) on the Number and Function of Circulating Endothelial Progenitor Cells in Patients With Angina Pectoris|
- The number of circulating endothelial progenitor cells in peripheral blood (before and one week after treatment)
- Brachial artery endothelial function (before and one week after treatment)
- CCS angina class (before and one week after treatment)
|Study Start Date:||August 2004|
|Estimated Study Completion Date:||January 2006|
ECPT is a non-invasive approach for increasing blood flow to the heart in patients with myocardial ischemia. ECPT produces beneficial effects in coronary artery disease (CAD) patients. However, the exact mechanisms of ECPT action are not defined yet. Evidence has now accumulated that bone marrow-derived cells with angiogenic capability, termed EPCs, circulate in the blood of adults. EPCs possess the ability to home to sites of ischemia and contribute to neoangiogenesis.
We prospectively study CAD patients [Canadian Cardiovascular Society (CCS) angina class II-IV], before and after ECPT , and compare them with age- and sex-matched controls. Peripheral blood CD34+ cells, EPCs (CD34/VEGFR2+ cells), EPC colony forming units (CFUs) and brachial artery endothelial function is assessed prior to and after ECPT. Percent improvement in endothelium-dependent brachial artery flow-mediated dilatation (%FMD) is assessed using high-resolution ultrasound.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00272571
|Neufeld cardiac research institute, Sheba medical center|
|Tel Hashomer, Israel|
|Principal Investigator:||Jonathan Leor, Prof.||Chaim Sheba Medical Center|